ClinicalTrials.gg
CompletedNCT05328778Updated Sep 21, 2026

Pharmacokinetics and Pharmacodynamics of Sugammadex Dosed by Corrected Body Weight for Reversal of Vecuronium in Obese Patients

A Phase 4 interventional study of Sugammadex in Pharmacokinetics, sponsored by Guangzhou General Hospital of Guangzhou Military Command. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Guangzhou General Hospital of Guangzhou Military Command · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to illustrate pharmacokinetics of sugammadex in reversal of vecuronium-induced neuromuscular blockade in patients during laparoscopic surgery

Read the detailed description

48 patients undergoing laparoscopic surgery were divided into 3 groups according to body mass index (BMI), including normal weight group(A group,n=16,18.5kg/m² ≤ BMI ≤ 24.9kg/m²),obese group (B group, n=16, 25≤BMI≤39.9kg/m²) and morbidly obese group (C group, n=16, BMI≥40kg/m²).

Vecuronium was continuous infusing to maintain moderate neuromuscular blockade during the laparoscopic surgery and stopped infusing after the laparoscopic procedure. A single dose administration of sugammadex (Sug) 2.0mg/kg according to ideal body weight (IBW) was given at the reappearance of the second twitch of the train-of-four (TOF) response.

On one hand, venous blood samples were obtained before administration of Sug and at 2, 3, 5, 10, 15, 20, 30, 60 minutes and 2, 4, 6, 8 hours after administration of Sug to determine plasma concentration of Sug using HPLC-MS. On the other hand, time from start of administration of Sug to recovery of TOF ratio to 0.9 and other clinical indicators were also recorded.

02

Conditions studied

  • Pharmacokinetics

Keywords

  • Sugammadex
  • Laparoscopic Surgery
03

In context

Lead sponsor

Guangzhou General Hospital of Guangzhou Military Command is the lead sponsor of 46 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ASA: Ⅰ\~Ⅲ
  2. ≥25kg/m²
  3. Patients receiving bariatric surgery.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women
  2. Neuromuscular diseases
  3. Malignant hyperthermia or allergic history during general anesthesia
  4. Drugs that react with rocuronium and vecuronium were taken
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Normal Weight group

    n=16, 18.5kg/m² ≤ BMI ≤ 24.9kg/m²

    Drug: Sugammadex

  • Experimental
    Obese group

    n=16, 25≤BMI≤39.9kg/m²

    Drug: Sugammadex

  • Experimental
    Morbidly Obese group

    n=16, BMI≥40kg/m²

    Drug: Sugammadex

Interventions

  • Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).

    Also known as: Bridion, Org 25969

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of Sugammadex

    venous blood samples were obtained

    Time frame: 0, 2, 3, 5, 10, 15, 20, 30, 60 minutes and 2, 4, 6, 8 hours

  2. TOF ratio of Recovery Time

    time from start of administration of Sug to recovery of TOF ratio to 0.9 and other indicators

    Time frame: TOF ratio at 30, 60, 90, 120, 150 seconds after administration

07

Study locations

1 site
  • Guangzhou Military Region General Hospital, Department of Anesthesiology
    Guangzhou, Guangdong 510010, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Jan 2025, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2022
First posted
Apr 14, 2022
StartActual
Apr 14, 2022
Primary completionActual
Jan 1, 2025
CompletionActual
Apr 1, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05328778
Lead sponsor
Guangzhou General Hospital of Guangzhou Military Command
Responsible party
bo xu (Clinical Professor, Guangzhou General Hospital of Guangzhou Military Command) — Principal investigator
First posted
Apr 14, 2022
Start date
Apr 14, 2022
Primary completion
Jan 1, 2025
Completion
Apr 1, 2026
Last update
Sep 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sugammadex

Start the discussion